Headline
Smith & Nephew cuts full-year revenue guidance to c.4% from c.6% as Orthopaedics stalls, standing out on a heavy results day otherwise weighted to reaffirmations and upgrades.
What UK Plc said today
The one clear negative is SN., which lowered FY26 revenue guidance to c.4% growth (from c.6%) after Orthopaedics and Advanced Wound Management both printed underlying growth of -0.1% in H1; trading profit, FCF and ROIC guidance were held. Property landlord CLI also cut, guiding 2026 EPS to 4.6–5.5p as leasing came in "slower than expected".
Against that, the day skews positive. KLR delivered H1 revenue +10.3% and lifted its dividend 57%, sitting on a record £1.9bn order book and confirming performance in line with recently upgraded expectations. SYNT upgraded FY26 to "slightly ahead" of market on H1 EBITDA +16.4%, though it flagged c.£6m of that as a one-off benefit from Iran-related competitor disruption. HSBA nudged banking NII guidance to "at least $46bn" from "around $46bn", with RoTE of 18.2% and a $1bn buyback. FRES posted revenue +74.7% on silver +134%/gold +47% price tailwinds and more than doubled the interim dividend. BAG, MPAL, VUL and WVIA all guided "ahead" in trading updates, with BAG pointing to double-digit full-year revenue growth.
Reaffirmers dominated: CTEC narrowed organic growth to 5.5–6.5% (from 5–7%) after a $69m InnovaMatrix impairment tied to a >85% Medicare price cut, but held margin and EPS targets and launched a $200m buyback; DOM held guidance with LFL sales +4.9%; ROR reaffirmed but flagged Oil & Gas recovery as "more gradual"; TPK expects H2 comparable to a soft H1 (revenue -1.8%); FTC, SBRE, XPP, CTA, FADL, TRB all in line.
Capital return remained the dominant theme: buybacks announced or extended at CTEC ($200m), RKT (£500m programme, £150m first tranche), SN. ($500m), KLR (£100m) and SBRE (£5m), alongside dividend hikes at FRES (+108.7%), KLR (+56.8%), CTEC (+15.4%) and DOM (+2.8%).
Statistical releases
No scheduled ONS releases today.
Policy / monetary
HMT published a joint statement with the U.S. Treasury following the 13th UK–U.S. Financial Regulatory Working Group meeting, plus preparer guidance for Whole of Government Accounts 2025–26. Nothing market-moving; no BoE items.
Themes
- Guidance dispersion by end-market: Industrials with infrastructure/defence exposure (KLR, FTC, SYNT) are upgrading or running ahead, while consumer/property/healthcare-devices names (SN., CLI, TPK) are cutting or flatlining. ROR's split — CPI stronger, Oil & Gas weaker — sits on the same fault line internally.
- Geopolitics as a P&L line item: SYNT quantified a £6m EBITDA benefit from Iran-conflict supply disruption to competitors and explicitly said it won't recur. KLR and KETL both cite Iran/Middle East as supply-chain and commodity risks; HSBA retains Middle East conflict language in its risk framework. The same event is a windfall for one and a headwind for others.
- Capital return over M&A firepower: Even names with stretched leverage (SN. net debt/EBITDA 1.8x, CTEC 2.3x) are prioritising buybacks over deleveraging, suggesting confidence in H2 cash generation is broad-based despite mixed top-line signals.